Danameco (DNM): small-cap medical supplier with recovery in 2025 but illiquid stock and low-confidence DCF
Intrinsic value VND 5,717 vs market VND 5,100 — implied upside 12.1% (model confidence: low).
Tổng quan doanh nghiệp
Tổng Công ty Cổ phần Y tế Danameco (DNM) is an UPCom-listed medical equipment and services company in the Thiết bị và Dịch vụ Y tế ICB3 industry. The firm provides medical supplies and related services to hospitals and clinics; revenue is seasonal and depends on institutional procurement cycles. DNM is a micro/ small-cap franchise: issued shares 5,253,070 and low daily liquidity (avg volume 2-week: 43 shares), which constrains free-float trading and makes market moves choppy.
The company reported a revenue rebound to VND 257.7 bn in 2025 from VND 196.8 bn in 2024 after a dip from VND 217.4 bn in 2023. Profitability recovered to VND 10.1 bn net profit in 2025 after losses in 2023–24. Balance sheet size has contracted (total assets VND 242.2 bn in 2025 vs VND 305.6 bn in 2023). Top-three individual shareholders collectively own c. 62.5%, indicating concentrated ownership and potential control influence over corporate actions and payouts.
Luận điểm đầu tư
DNM's operating recovery in 2025 (revenue VND 257.7 bn and net profit VND 10.1 bn) suggests the business can return to modest profitability after the near-breakeven 2024. Key attractive financial signals: a very low P/E multiple of 2.7x and EV/EBITDA of 4.1x indicate the market is valuing the company at depressed multiples versus broader healthcare peers. Gross margin of 16.7% and EBIT margin of 9.8% show there is an operating margin buffer to support earnings if sales stabilize.
However, risks and model limitations temper conviction. Our blended FCF DCF implies an intrinsic value of VND 5,717 per share (DCF weight 70%), only 12.1% above the current match price of VND 5,100, and the model confidence is explicitly low. The valuation relies on a 10% WACC and 4.0% terminal growth with a large terminal value contribution (TV pct 57.07%). Given the small free float, average two-week volume of 43 shares, and the model's sanity flags 'illiquid' and 'illiquid_upside_capped', execution risk and marketability are material concerns. Earnings quality is high (81.5/100), and there are no forensic M-Score flags, but ownership concentration (top three = 62.5%) increases governance and minority-liquidity risk.
Overall, the stock's implied upside of 12.1% is within a moderate range but our low model confidence and the company's illiquidity mean the incremental return is unlikely to sufficiently compensate for execution and marketability risks. The valuation is sensitive to the DCF inputs (WACC, terminal growth) and to the projection of stable FCF given historical revenue volatility (3-year revenue CAGR shows a negative historical CAGR component in the model inputs: -6.76%).
Diễn giải định giá
Blend of a DCF (70%) and an implied PE overlay (30%): the primary signal is the DCF-derived intrinsic value calibrated via isotonic mapping.
- Base projected free cash flow (base_fcf): VND 11,528,101,484 (model input)
- WACC: 10.0% and terminal growth 4.0% (model_inputs.wacc and terminal_g)
- Terminal value accounts for 57.07% of total value (tv_pct 0.5707)
- Net debt: VND 139.7 bn (model input) reduces enterprise value to equity value
- Low liquidity flags and recalibrated confidence (model confidence: low) limit precision
The blended intrinsic VND 5,717 implies a 12.1% upside to the current price but model confidence is low. The valuation is highly sensitive to the WACC and terminal-growth assumptions and to the large terminal-value share (57%). Given small free float and illiquidity, treat the point estimate as directional rather than precise.
Các luận điểm cần cân nhắc
- Revenue rebound to VND 257.7 bn in 2025 from VND 196.8 bn in 2024 shows recovery momentum that could lift earnings further.
- Very attractive multiples versus peers: P/E 2.7x and EV/EBITDA 4.1x provide upside if margins and sales sustain.
- High earnings-quality score (81.5/100) and absence of M-Score or forensic red flags reduce accounting-manipulation concern.
- Low model confidence and large terminal-value share (TV 57.07%) make DCF intrinsically fragile to small input changes.
- Severe illiquidity (avg volume 43 shares) and concentrated ownership (top three = 62.5%) increase execution and liquidity risk for investors.
- Historical revenue volatility and negative historical CAGR input (-6.76%) mean the 4.0% steady growth assumption may be optimistic.
- Net debt of VND 139.7 bn is material relative to enterprise size and can pressure returns if cash-generation weakens.
Bối cảnh ngành
The Thiết bị và Dịch vụ Y tế sector is driven by hospital procurement cycles, state tenders and private hospital expansion. In Vietnam, SOE and state-linked entities in healthcare may face legacy procurement channels and pricing pressure; regulatory changes in public procurement or pricing could materially affect small suppliers. VAS accounting differences can make cross-border and peer comparisons harder: inventory and revenue recognition timing matter for equipment suppliers.
Peer valuation dispersion is wide: sector median implied upside is c. 12.0%, with some listed peers showing >36% upside and others negative. DNM sits close to the sector median implied upside but differs materially on liquidity and scale. Foreign ownership room for DNM appears non-binding (foreign_room ~2,439,710 shares) but limited trading activity means foreign participation may remain low. For banks/financial firms the VAMC bond mechanism can mask credit risks; for healthcare firms like DNM, working-capital funding and receivables from hospitals are the key funding risks rather than banking-sector idiosyncrasies.
Yếu tố rủi ro
- Illiquidity risk: average two-week volume is 43 shares, increasing market-impact costs and widening bid/ask spreads.
- Owner concentration: top three individuals own c. 62.5%, raising governance and minority-exit risk.
- Model sensitivity: DCF relies on WACC 10% and terminal growth 4.0%; small input changes materially alter the VND 5,717 intrinsic value.
- Revenue volatility: historical inputs include a negative historical CAGR (-6.76%), and 3-year revenues swung between VND 196.8–257.7 bn.
- Leverage and net debt: net debt VND 139.7 bn is sizable for a company with total assets VND 242.2 bn (2025); refinancing or weaker cash generation could strain liquidity.
- Market/regulatory risk: changes in public procurement rules or hospital budgets could compress demand or extend receivable cycles.
Yếu tố có thể tác động
- Sustained revenue growth above VND 260–300 bn range or repeatable quarterly profit expansion would validate model assumptions.
- Any improvement in liquidity or a block sale that increases free-float could narrow the liquidity premium and re-rate multiples.
- Disclosures that materially reduce model uncertainty (e.g., long-term contracts, higher visibility on FCF) could raise model confidence and intrinsic valuation.
Đánh giá dấu hiệu kế toán
No M-Score data or explicit forensic red flags are present; the dataset shows a high earnings-quality score of 81.5, which suggests reported results are reasonably reliable. However, absence of red flags in the input does not eliminate the need for diligence: concentrated ownership (top three = 62.5%) and illiquidity increase the non-financial governance risk that can be as impactful as accounting concerns.
Lịch sử định giá
The coverage model has a 12-year track record (2015–2026) with a hit rate of 63.6% (model directional calls >10% matched next-year price direction roughly 7.6 of 12 years). Average historical upside on calls was large (avg_upside_pct 135.4%), but that figure is skewed by outliers and small-cap volatility. Given the low current model confidence and the stock's illiquidity, historical hit rate deserves cautious interpretation rather than high conviction.
Nội dung do mô hình ngôn ngữ tạo ngày 2026-08-10 từ kết quả mô hình và báo cáo tài chính trên trang này; số liệu có thể phản ánh thời điểm đó. Đây là phân tích mô tả, không cấu thành khuyến nghị mua, bán hoặc nắm giữ.